Dublin 9

• Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended recruitment
  2023-507889-89-00 5 2016-02-19 Respiratory tract infection
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET Ended recruitment
  2024-516137-13-00 5 2014-12-18 Metastatic Prostate Cancer
• SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive N … Ended recruitment
  2024-516801-22-00 5 2012-04-26 Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-N
• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended
  2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended
  2023-507680-19-00 4 2024-11-28 Sjögren’s Syndrome
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer
• Phase 2 study comparing SAR447537 to plasma-derived A1PI therapy for AATD emphysema Ended
  2023-508084-76-00 4 2024-05-31 Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
• A Study of the Efficacy, Safety, and Tolerability of KAN-101 in Participants With Celiac Disease Ended
  2023-507240-37-00 4 2024-04-30 celiac disease
• An open-label, cross-over, multi-site, prospective, phase IIb study of effects on circadian rhythms and quality of life of modifieddual-rele … Ended
  2023-503584-42-00 4 2023-12-22 Addison’s Disease
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• Phase 3 Study Comparing Zimberelimab with Domvanalimab to Pembrolizumab in Advanced Non-Small Cell Lung Cancer Ended
  2022-503071-28-00 5 2023-08-31 Squamous Non-small cell Lung Cancer
• Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended
  2022-502000-73-00 5 2023-08-11 Focal Onset Seizures
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 5 2023-06-08 Moderately to severely active ulcerative colitis
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effe … Ended
  2023-510317-26-00 4 2023-02-07 Amyotrophic Lateral Sclerosis
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 10 2022-09-13 venous thromboembolism (VTE) in patients with gastrointestinal/genitou
• Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended
  2022-500363-12-00 4 2022-08-24 SARS CoV-2 (COVID-19)
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• Cohort study of human mpox virus disease Ended
  2022-501132-42-00 6 2022-08-02 Monkeypox virus disease
• Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants with Relapsed or Refractory Multiple Myeloma (DREAM … Ended
  2023-508213-16-00 4 2022-03-15 Multiple Myeloma
• A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis Ended
  2023-508511-23-00 5 2021-12-02 Amyotrophic Lateral Sclerosis (ALS)
• Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma. … Ended
  2024-516945-37-00 2 2021-11-04 Relapsed/ refractory multiple myeloma
• A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Plac … Ended
  2024-511066-36-00 5 2021-10-13 Light Chain (AL) Amyloidosis
• Lighthouse II study Ended
  2024-517054-94-00 5 2021-07-05 AMYOTROPHIC LATERAL SCLEROSIS

Showing 97–120 of 134 trials